Key result
Vitamin K-antagonists lead to decreased levels of serum osteocalcin and low affinity for hydroxyapatite in both sheep and human subjects, remaining low for at least several years.
Why the study?
Does oral anticoagulant therapy with vitamin K-antagonists affect circulating osteocalcin levels and its affinity for hydroxyapatite in sheep and humans?
Observational
Does oral anticoagulant therapy with vitamin K-antagonists affect circulating osteocalcin levels and its affinity for hydroxyapatite in sheep and humans?
Vitamin K-antagonists persistently decrease serum osteocalcin levels and its affinity for hydroxyapatite in both sheep and humans.
May warrant bone health consideration with long-term VKAs; leaves open fracture risk implications in anticoagulated patients.
In this paper we present the following observations: 1) In sheep vitamin K-antagonists like phenprocoumon induce a decrease of the serum levels of osteocalcin (bone Gla-protein) and of the affinity of the circulating osteocalcin for hydroxyapatite. 2) In sheep vitamin K counteracts the effect of phenprocoumon on the blood coagulation system, but not that on the osteocalcin production. 3) In human subjects vitamin K-antagonists also lead to decreased levels of serum osteocalcin and a low affinity of the protein for hydroxyapatite. 4) These two variables reached steady-state levels within 24 h after the start of oral anticoagulant treatment and--at continuation of the therapy--they remained low for at least several years.
No takes yet. Share an insight, caveat, or question.
Haarlem et al. (1988) conducted an observational in Oral anticoagulant therapy. Vitamin K-antagonists was evaluated on Serum levels of osteocalcin and affinity for hydroxyapatite. Vitamin K-antagonists lead to decreased levels of serum osteocalcin and low affinity for hydroxyapatite in both sheep and human subjects, remaining low for at least several years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: